The FDA has approved a subcutaneously administered version of the brand-name trastuzumab, Herceptin. The new formulation, trastuzumab and hyaluronidase-oysk, is a combination of the anticancer agent trastuzumab and an endoglycosidase that allows for the administration of higher volumes and enhanced absorption, and it has been approved under the name Herceptin Hylecta.
The FDA has approved a subcutaneously administered version of the brand-name trastuzumab, Herceptin. The new formulation, trastuzumab and hyaluronidase-oysk, is a combination of the anticancer agent trastuzumab and an endoglycosidase that allows for the administration of higher volumes and enhanced absorption, and it has been approved under the name Herceptin Hylecta.
Approval of the subcutaneously administered product was based on 2 randomized trials. First, the HannaH trial compared the subcutaneous trastuzumab to the infused product in 596 patients with HER2-positive breast cancer. Patients were randomized to receive 8 cycles of chemotherapy with either the subcutaneous or the intravenous trastuzumab, followed by surgery and an additional 10 cycles of their assigned trastuzumab therapy. In total, 45.5% of patients in the subcutaneous arm and 40.7% of patients in the intravenous arm had a pathological complete response.
Second, the SafeHER trial, a 2-cohort, non-randomized, multinational, open-label trial, assessed the overall safety and tolerability of the subcutaneous trastuzumab together with chemotherapy in 1864 patients with HER2-positive breast cancer. The trial, in which patients received a fixed dose of the drug every 3 weeks for 18 cycles, confirmed the safety and tolerability of the fixed dose of the drug.
Not only does a subcutaneous injection of trastuzumab provide advantages for patients who may prefer the faster injection to a lengthy visit to an infusion center, the newly approved formulation has also been shown to save on costs in other regulatory territories where the drug is already widely in use. The subcutaneous formulation of the product is approved and available in the European Union, where research from 3 centers in Spain demonstrated that using the subcutaneous product results in reduced per-patient costs for an 18-cycle treatment of €1132.43 ($1335.68). Those savings derive from provider time costs, the costs of consumables, and the cost of trastuzumab, as well as indirect costs such as reduced productivity associated with infusions.
The cost savings associated with the formulation could be a reason for concern on the part of biosimilar developers. To date, the FDA has approved 3 biosimilar trastuzumab products: Mylan and Biocon’s Ogivri, Celltrion’s Herzuma, and Samsung Bioepis’ Ontruzant, all of which have yet to launch in the US market. While it remains to be seen how deep a discount any of the biosimilar makers will offer for their intravenously administered products upon launch, questions remain about how substantial those discounts will need to be to overcome the appeal and the potential cost savings represented by a subcutaneous formulation of the originator drug.
However, some researchers have voiced questions about the subcutaneous version of the product that may make biosimilars a more appealing cost-saving option. Writing in Pharmaceutical Medicine, authors recently pointed out that one of the main concerns with trastuzumab’s biological activity is its interaction with pertuzumab to treat HER2-positive cancer, and interactions among HER2 receptor, pertuzumab, and trastuzumab—anti-drug antibody complexes have not yet been fully evaluated with respect to the subcutaneous product. The phase 3 SAPPHIRE study did evaluate the safety, tolerability, and efficacy of intravenous pertuzumab plus subcutaneous trastuzumab and a taxane, but the small population enrolled in the study made it difficult to draw conclusions.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Duke Publishes Recommendations for Developing CGT Biosimilars
October 9th 2024Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex biologics limit competition, requiring policies that support the development of biosimilars to enhance affordability and patient access.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.